Tuesday, November 10, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 6, 2026

TEN Holdings Reports Third Quarter 2026 Financial Results

View original at finance.yahoo.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Third quarter revenue increased 17.9% year over year to $640,000 from completed customer engagements initiated in prior periods plus new customers.

    60% confidence
  • Over the past 12 months the company reduced its annual operating cost structure by approximately $2.5 million through cost reductions, process improvements and AI-driven tools.

    60% confidence
  • Short-term related-party borrowings fell from $4.6 million at the start of the year to about $0.1 million at September 30, 2026; total liabilities fell ~74% from $7.7 million at year-end 2025 to $2.0 million.

    60% confidence
  • Q3 results include two non-recurring expenses: a $1.8 million write-off of previously capitalized service contracts and about $0.5 million in legal expenses; excluding them, underlying SG&A declined year over year.

    60% confidence
  • TEN represents an important step toward a scalable, SaaS-driven business model, unifying tools to create, manage, deliver and measure digital experiences.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,558 source documents archived
Query this data → isubstrate.com